Lv3
400 积分 2022-09-25 加入
Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)
2天前
已完结
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma
2天前
已完结
[CAR T-cell therapy for T cell malignancies: challenges and recent advances]
1个月前
已完结
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
1个月前
已完结
Engineered T cell therapy for central nervous system injury
1个月前
已完结
Fratricide-resistant CD7-CAR T cells in T-ALL
2个月前
已完结
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
3个月前
已完结
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial
3个月前
已完结
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial
9个月前
已完结
CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
9个月前
已完结
皖公网安备34019202002308
